Skip to main content
MedPathMedPath Home
Clinical Trials/PACTR201508001241218
PACTR201508001241218
Recruiting
未知

Botulinum Neurotoxin as first line therapy in the management of Childhood esotropia

Not provided0 sites250 target enrollmentAugust 17, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEye DiseasesSurgeryPaediatricschildhood strabismus

Overview

Phase
未知
Intervention
Not specified
Conditions
Eye Diseases
Sponsor
Not provided
Enrollment
250
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 17, 2015
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Not provided

Eligibility Criteria

Inclusion Criteria

  • •Children between the ages of 6 months to 6 years with essential esotropia.
  • •Children with partially accommodative esotropia who require surgery to correct residual angle.
  • •Children diagnosed with acquired non accommodative esotropia.
  • •Children with concomitant esotropia secondary to neurodevelopmental disorders.

Exclusion Criteria

  • •Any concomitant esotropia corrected fully with spectacle correction.
  • •Significant associated vertical misalignment such as dissociative vertical deviation or inferior oblique overaction requiring surgery for these conditions.
  • •Strabismus secondary to ocular pathology.
  • •incomitant esotropia.
  • •Patients refusing to be randomised.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Botuline toxine als nieuwe behandeling voor onverklaarde schokken.psychogenic movement disorder
NL-OMON28532Academic Medical CentreMeibergdreef 91105 AZ Amsterdam54
Active, not recruiting
Not Applicable
Behandling med botulinumtoxin vid neurogen blåsfunktionsstörningThe trial addresses patients with severe symptoms of neurogenic detrusor overactivity (urgency and/or urge incontinence). Eligible are those patients who have failed conservative treatment such as behavioral techniques, physiotherapy, intermittent catheterisation or pharmacotherapy.
EUCTR2005-003068-47-SERegion Skåne, Universitetssjukhuset i Lund, Urologiska kliniken40
Active, not recruiting
Phase 1
How affect the salivary gland treatment with Botulinum neurotoxin type A oral health in patients suffer for drooling?HypersalivationMedDRA version: 18.0Level: LLTClassification code 10020746Term: HypersalivationSystem Organ Class: 100000004856Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
EUCTR2015-000682-30-EETartu University Hospital90
Recruiting
Not Applicable
The Effect and safety of Botox in the treatment of patients with Spinal injury associated with Human T-cell Lymphotrofic Virus type I
RBR-67ynvtHospital Universitário Professor Edgard Santos
Not yet recruiting
Not Applicable
Effectiveness of Botulinum Toxin Infiltration for treatment of upper limb dysfunctions after treatment for breast cancer.Patients treated for breast cancer and chronic pain (> 3 months) at the breast region
NL-OMON26807Z Leuven50